A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Fgfr Mutations - Lung
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic or is surgically unresectable. 2) Radiographically measurable disease. Tumor lesions located in a previously irradiated area, or in an area subjected to other loco-regional therapy, are considered measureable if progression has been clearly demonstrated in the lesion. 3) Documentation of an FGFR1-3 gene mutation or translocation. 4) Must have objective progression after at least 1 prior therapy, and must have no therapy available that is likely to provide clinical benefit. Participants who are intolerant to or decline the approved therapy are eligible only if they have no therapy available that is likely to provide clinical benefit.

You may not be eligible for this study if the following are true:

  • 1) Prior receipt of a selective FGFR inhibitor. 2) Receipt of anticancer medications or investigational drugs for any indication or reason within 28 days before first dose of pemigatinib. 3) Concurrent anticancer therapy. 4) Cannot be a candidate for potentially curative surgery.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.